Clinical trials: Depression NOS
Major Depressive Disorder (MDD)
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
- Trial name
- NCT00057239
- Testing
- Radafaxine
- Where
- 29 sites in United States
- Volunteers
- 546 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction, Depression
Depression Related Improvement With Vardenafil for Erectile Response
The study will last three months. During the first month of treatment the subject will receive either 10 mg vardenafil or placebo.
- Trial name
- DRIVER (NCT00661219)
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 280 people
- Sponsor
- Bayer
Post Surgical Respiratory Failure, Respiratory Complication
Advanced Prediction of Respiratory Depression Episode Using the Linshom Continuous Predictive Respiratory Sensor
Investigators will enroll 320 patients who will undergo non-cardiac surgery, receive supplemental oxygen via face mask, and will be on a continuous pulse oximetry monitor in the Post Anesthesia Care Unit (PACU).
- Trial name
- NCT06744790
- Testing
- Linshom Continuous Predictive Respiratory Monitoring
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- Linshom Medical, Inc.
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Major Depressive Episode
The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition
This multi-site, double-blind, randomized, sham-controlled mechanistic trial aims to test the effects of Magnus Neuromodulation System (MNS) with Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) Technology on…
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- SAINT®SC (NCT03693105)
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Depression in Patients With Bipolar Disorder
Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00622245
- Testing
- Lu AA34893, Quetiapine fumarate
- Where
- 50 sites in Australia, Austria and 16 more
- Volunteers
- 166 people
- Sponsor
- H. Lundbeck A/S
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Major Depressive Disorder
ALTO-300 in Depression (ALTO-300-004)
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05157945
- Testing
- ALTO-300 PO Tablet
- Where
- 4 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alto Neuroscience
Schizophrenia, Affective Symptoms
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.
- Trial name
- AFFECT (NCT01534936)
- Where
- 53 sites in Hungary
- Volunteers
- 2,153 people
- Sponsor
- AstraZeneca
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
- Trial name
- NCT04830215
- Testing
- Brexpiprazole
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression
The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.
- Trial name
- NCT03386448
- Testing
- Scopolamine and naltrexone
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- The Taub Group
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Post Partum Depression
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
- Trial name
- NCT03665038
- Testing
- Brexanolone
- Where
- 17 sites in United States
- Volunteers
- 28 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Depression, Post Traumatic Stress Disorder
Ketamine and Epigenetic Aging
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age…
- Trial name
- NCT05294835
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic